Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Active Primary Sjögren's Disease
NCT07404865Phase 3Recruiting
- Sponsor
- Vor Bio
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 3 trial of telitacicept in Sjögren's syndrome, sponsored by Vor Bio. Started Feb 2026; status: recruiting.
02
Drugs
telitacicept
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT07404865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07404865.